When an online pharmacy discovered the presence of a carcinogenic contaminant in batches of the heartburn medication Zantac it was selling, the find triggered a global recall of the drug. Now, details are coming to light that the presence of the contaminant may not have been as much of a surprise to Sanofi; the drug’s manufacturer, as was first indicated.
Zantac, otherwise known by its chemical name ranitidine, was ...
continue reading...
There is no way to overstate the importance of the discovery of insulin and the impact it has had on the world. Insulin has either extended or saved the lives of countless diabetics in the nearly 100 years since the discovery occurred. While the event and the attention it would bring would lead to significant strains on the interpersonal relationships of those involved, the researchers nonetheless ...
Sanofi and Regeneron’s new cholesterol drug, Praluent, has received a nod of approval from the U.S. Food and Drug Administration (FDA). Approval comes after the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) found that sufficient evidence existed that the benefits of Praluent outweighed the risks of the drug gave a positive recommendation.
The FDA advisory committee based their recommendation on a study of over 5,000 patients in a double-blind, ...
continue reading...Nasdaq.com reports that the U.S. Food and Drug Administration (FDA) has approved Praluent, the first of a new and highly anticipated class of cholesterol medications. The drug, jointly developed by Sanofi SA and Regeneron Pharmaceuticals, will provide an alternative to patients who have not had success with statins like Pfizer’s controversial Lipitor.
From 1996 until its patent expired in 2011, Lipitor was the world’s best-selling drug, with an estimated $125 billion in ...
continue reading...
